Pancreatic Cancer Research

Clinical trialPhase 2Withdrawn

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

A Single Arm Phase 2 Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Outcome
Stopped earlyHalozyme isn't allowing this trial to move forward until their current clinical trial results are released. (Other)
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Planned start
15 November 2019
Planned end
31 July 2021
Enrollment
0 participants
Sites
0
Primary outcomes
Progression Free Survival (PFS) rate
Sponsor type
Academic / other
Results posted
No
Last update
9 January 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.

Detailed description public domain (ClinicalTrials.gov)

To determine the efficacy of gemcitabine plus nab-paclitaxel in combination with PVHA and pembrolizumab as measured by progression free survival (PFS). Hypothesis: The combination of gemcitabine, nab-paclitaxel, PVHA and pembrolizumab will improve PFS compared to the historical control for chemotherapy. 3.2 Secondary Objectives \& Hypotheses 1. Objective: To estimate median overall survival (OS) 2. Objective: To determine the overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). 3. Objective: To determine the toxicity and tolerability of gemcitabine plus nab-paclitaxel with PVHA and pembrolizumab. Hypothesis: The combination of gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab will be safe and improve OS and ORR compared to the historical control for chemotherapy. 3.3 Exploratory Objective 1. Objective: To evaluate pre-treatment and on-treatment PD-L1 and hyaluronan (HA) status and correlate with PFS, ORR, and OS. 2. Objective: To measure the stromal alterations and stromal degradation of hyaluronan and correlate with clinical benefit. 3. Objective: To quantify the pre-treatment and on-treatment change in immune effector cells and correlate with clinical benefit. 4. Objective: To cryopreserve additional tumor tissue for future analysis, including but not limited to DNA and RNA sequencing. 5. Objective: To create organoid cultures from core biopsy specimens for future studies.